Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2024

Open Access 01-12-2024 | Thrombotic Thrombocytopenic Purpura | Research

Stress-induced hyperglycemia is associated with the mortality of thrombotic thrombocytopenic purpura patients

Authors: Lingling Hu, Jing Wang, Xiaxia Jin, Guoguang Lu, Meidan Fang, Jian Shen, Tao-Hsin Tung, Bo Shen

Published in: Diabetology & Metabolic Syndrome | Issue 1/2024

Login to get access

Abstract

Background

Thrombotic thrombocytopenic purpura (TTP) is a rare thrombotic microangiopathy with a rapid progression and high mortality rate. We aimed to explore early risk factors for mortality in patients with TTP.

Methods

We conducted a retrospective analysis of 42 TTP patients that were admitted to our hospital between 2000 and 2021, with a median age of 49 (29–63) years. Risk factors for mortality were evaluated using multivariate logistic regression. Receiver operating characteristic curve analysis was used to determine the cut-off value of glucose for predicting mortality in patients, which was validated by comparison to a similar cohort in the published literature.

Results

Elevated glucose level and reduced red blood cells (RBC) counts were risk factors for mortality in patients with TTP (glucose, odds ratio and 95% confidence interval: 2.476 [1.368–4.484]; RBC, odds ratio and 95% confidence interval: 0.095 [0.011–0.799]). The area under the curve of glucose was 0.827, and the cut-off value was 9.2 mmol/L, with a sensitivity of 75.0% and specificity of 95.8%. A total of 26 cases from the validation cohort had a sensitivity of 71.0% and a specificity of 84.0%. The change trends of the TTP-related laboratory indices differed during hospitalization.

Conclusion

Hyperglycemia at admission and unstable blood glucose levels during hospitalization may be potential predictors of mortality for TTP patients. The improved prognosis was associated with the recovery of platelet counts and a significant decrease in serum lactate dehydrogenase after five days of treatment.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sukumar S, Lammle B, Cataland SR. Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management. J Clin Med (2021) 10(3). Epub 2021/02/06. https://doi.org/10.3390/jcm10030536. IF: 3.9 Q2 B3 IF: 3.9 Q2 B3 IF: 3.9 Q2 B3 IF: 3.9 Q2 B3 IF: 3.9 Q2 B3 IF: 3.9 Q2 B3 IF: 3.9 Q2 B3. Sukumar S, Lammle B, Cataland SR. Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management. J Clin Med (2021) 10(3). Epub 2021/02/06. https://​doi.​org/​10.​3390/​jcm10030536. IF: 3.9 Q2 B3 IF: 3.9 Q2 B3 IF: 3.9 Q2 B3 IF: 3.9 Q2 B3 IF: 3.9 Q2 B3 IF: 3.9 Q2 B3 IF: 3.9 Q2 B3.
2.
go back to reference George JN. Clinical practice. Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2006;354(18):1927–35. https://doi.org/10.1056/NEJMcp053024. IF: 158.5 Q1 B1 IF: 158.5 Q1 B1 IF: 158.5 Q1 B1 IF: 158.5 Q1 B1 IF: 158.5 Q1 B1 IF: 158.5 Q1 B1 IF: 158.5 Q1 B1. Epub 2006/05/05. George JN. Clinical practice. Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2006;354(18):1927–35. https://​doi.​org/​10.​1056/​NEJMcp053024. IF: 158.5 Q1 B1 IF: 158.5 Q1 B1 IF: 158.5 Q1 B1 IF: 158.5 Q1 B1 IF: 158.5 Q1 B1 IF: 158.5 Q1 B1 IF: 158.5 Q1 B1. Epub 2006/05/05.
5.
go back to reference Kremer Hovinga JA, Coppo P, Lammle B, Moake JL, Miyata T, Vanhoorelbeke K. Thrombotic Thrombocytopenic Purpura. Nat Rev Dis Primers (2017) 3:17020. Epub 2017/04/07. https://doi.org/10.1038/nrdp.2017.20. IF: 81.5 Q1 B1 IF: 81.5 Q1 B1 IF: 81.5 Q1 B1 IF: 81.5 Q1 B1 IF: 81.5 Q1 B1 IF: 81.5 Q1 B1 IF: 81.5 Q1 B1. Kremer Hovinga JA, Coppo P, Lammle B, Moake JL, Miyata T, Vanhoorelbeke K. Thrombotic Thrombocytopenic Purpura. Nat Rev Dis Primers (2017) 3:17020. Epub 2017/04/07. https://​doi.​org/​10.​1038/​nrdp.​2017.​20. IF: 81.5 Q1 B1 IF: 81.5 Q1 B1 IF: 81.5 Q1 B1 IF: 81.5 Q1 B1 IF: 81.5 Q1 B1 IF: 81.5 Q1 B1 IF: 81.5 Q1 B1.
6.
go back to reference Scully M, Cataland S, Coppo P, de la Rubia J, Friedman KD, Kremer Hovinga J, et al. Consensus on the standardization of terminology in thrombotic Thrombocytopenic Purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017;15(2):312–22. https://doi.org/10.1111/jth.13571. IF: 10.4 Q1 B2 IF: 10.4 Q1 B2 IF: 10.4 Q1 B2 IF: 10.4 Q1 B2 IF: 10.4 Q1 B2 IF: 10.4 Q1 B2 IF: 10.4 Q1 B2. Epub 2016/11/22. Scully M, Cataland S, Coppo P, de la Rubia J, Friedman KD, Kremer Hovinga J, et al. Consensus on the standardization of terminology in thrombotic Thrombocytopenic Purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017;15(2):312–22. https://​doi.​org/​10.​1111/​jth.​13571. IF: 10.4 Q1 B2 IF: 10.4 Q1 B2 IF: 10.4 Q1 B2 IF: 10.4 Q1 B2 IF: 10.4 Q1 B2 IF: 10.4 Q1 B2 IF: 10.4 Q1 B2. Epub 2016/11/22.
7.
go back to reference Wang HX, Han B, Zhao YY, Kou L, Guo LL, Sun TW, et al. Serum D-Dimer as a potential New Biomarker for Prognosis in patients with Thrombotic Thrombocytopenic Purpura. Med (Baltim). 2020;99(13):e19563. https://doi.org/10.1097/MD.0000000000019563. IF: 1.6 Q3 B4 IF: 1.6 Q3 B4 IF: 1.6 Q3 B4 IF: 1.6 Q3 B4 IF: 1.6 Q3 B4 IF: 1.6 Q3 B4 IF: 1.6 Q3 B4. Epub 2020/03/30. Wang HX, Han B, Zhao YY, Kou L, Guo LL, Sun TW, et al. Serum D-Dimer as a potential New Biomarker for Prognosis in patients with Thrombotic Thrombocytopenic Purpura. Med (Baltim). 2020;99(13):e19563. https://​doi.​org/​10.​1097/​MD.​0000000000019563​. IF: 1.6 Q3 B4 IF: 1.6 Q3 B4 IF: 1.6 Q3 B4 IF: 1.6 Q3 B4 IF: 1.6 Q3 B4 IF: 1.6 Q3 B4 IF: 1.6 Q3 B4. Epub 2020/03/30.
8.
go back to reference Ali Abdelhamid Y, Kar P, Finnis ME, Phillips LK, Plummer MP, Shaw JE, et al. Stress hyperglycaemia in critically ill patients and the subsequent risk of diabetes: a systematic review and Meta-analysis. Crit Care. 2016;20(1):301. https://doi.org/10.1186/s13054-016-1471-6. IF: 15.1 Q1 B1 IF: 15.1 Q1 B1 IF: 15.1 Q1 B1 IF: 15.1 Q1 B1 IF: 15.1 Q1 B1 IF: 15.1 Q1 B1 IF: 15.1 Q1 B1. Epub 2016/09/30. Ali Abdelhamid Y, Kar P, Finnis ME, Phillips LK, Plummer MP, Shaw JE, et al. Stress hyperglycaemia in critically ill patients and the subsequent risk of diabetes: a systematic review and Meta-analysis. Crit Care. 2016;20(1):301. https://​doi.​org/​10.​1186/​s13054-016-1471-6. IF: 15.1 Q1 B1 IF: 15.1 Q1 B1 IF: 15.1 Q1 B1 IF: 15.1 Q1 B1 IF: 15.1 Q1 B1 IF: 15.1 Q1 B1 IF: 15.1 Q1 B1. Epub 2016/09/30.
9.
go back to reference Allford SL, Hunt BJ, Rose P, Machin SJ, Haemostasis, Thrombosis Task Force BCfSiH. Guidelines on the diagnosis and management of the thrombotic Microangiopathic Haemolytic Anaemias. Br J Haematol. 2003;120(4):556–73. https://doi.org/10.1046/j.1365-2141.2003.04049.x. IF: 6.5 Q1 B2 IF: 6.5 Q1 B2 IF: 6.5 Q1 B2 IF: 6.5 Q1 B2 IF: 6.5 Q1 B2 IF: 6.5 Q1 B2 IF: 6.5 Q1 B2. Epub 2003/02/18. Allford SL, Hunt BJ, Rose P, Machin SJ, Haemostasis, Thrombosis Task Force BCfSiH. Guidelines on the diagnosis and management of the thrombotic Microangiopathic Haemolytic Anaemias. Br J Haematol. 2003;120(4):556–73. https://​doi.​org/​10.​1046/​j.​1365-2141.​2003.​04049.​x. IF: 6.5 Q1 B2 IF: 6.5 Q1 B2 IF: 6.5 Q1 B2 IF: 6.5 Q1 B2 IF: 6.5 Q1 B2 IF: 6.5 Q1 B2 IF: 6.5 Q1 B2. Epub 2003/02/18.
10.
go back to reference Matsumoto M, Fujimura Y, Wada H, Kokame K, Miyakawa Y, Ueda Y, et al. Diagnostic and Treatment guidelines for thrombotic Thrombocytopenic Purpura (ttp) 2017 in Japan. Int J Hematol. 2017;106(1):3–15. https://doi.org/10.1007/s12185-017-2264-7. IF: 2.1 Q4 B4 IF: 2.1 Q4 B4 IF: 2.1 Q4 B4 IF: 2.1 Q4 B4 IF: 2.1 Q4 B4 IF: 2.1 Q4 B4 IF: 2.1 Q4 B4. Epub 2017/05/28. Matsumoto M, Fujimura Y, Wada H, Kokame K, Miyakawa Y, Ueda Y, et al. Diagnostic and Treatment guidelines for thrombotic Thrombocytopenic Purpura (ttp) 2017 in Japan. Int J Hematol. 2017;106(1):3–15. https://​doi.​org/​10.​1007/​s12185-017-2264-7. IF: 2.1 Q4 B4 IF: 2.1 Q4 B4 IF: 2.1 Q4 B4 IF: 2.1 Q4 B4 IF: 2.1 Q4 B4 IF: 2.1 Q4 B4 IF: 2.1 Q4 B4. Epub 2017/05/28.
12.
go back to reference Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, et al. American Association of Clinical Endocrinologists and American Diabetes Association Consensus Statement on Inpatient Glycemic Control. Diabetes Care. 2009;32(6):1119–31. https://doi.org/10.2337/dc09-9029. IF: 16.2 Q1 B1 IF: 16.2 Q1 B1 IF: 16.2 Q1 B1 IF: 16.2 Q1 B1 IF: 16.2 Q1 B1 IF: 16.2 Q1 B1 IF: 16.2 Q1 B1. Epub 2009/05/12. Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, et al. American Association of Clinical Endocrinologists and American Diabetes Association Consensus Statement on Inpatient Glycemic Control. Diabetes Care. 2009;32(6):1119–31. https://​doi.​org/​10.​2337/​dc09-9029. IF: 16.2 Q1 B1 IF: 16.2 Q1 B1 IF: 16.2 Q1 B1 IF: 16.2 Q1 B1 IF: 16.2 Q1 B1 IF: 16.2 Q1 B1 IF: 16.2 Q1 B1. Epub 2009/05/12.
13.
go back to reference Thrombosis, Hemostasis group HSCMA. [Consensus of Chinese experts on diagnosis and treatment of thrombotic Thrombocytopenic Purpura (Version 2012)]. Zhonghua Xue Ye Xue Za Zhi. 2012;33(11):983–4. Epub 2013/02/01. Thrombosis, Hemostasis group HSCMA. [Consensus of Chinese experts on diagnosis and treatment of thrombotic Thrombocytopenic Purpura (Version 2012)]. Zhonghua Xue Ye Xue Za Zhi. 2012;33(11):983–4. Epub 2013/02/01.
14.
go back to reference Sukumar S, Brodsky M, Hussain S, Yanek L, Moliterno A, Brodsky R, et al. Cardiovascular Disease is a leading cause of mortality among ttp survivors in clinical remission. Blood Adv. 2022;6(4):1264–70. https://doi.org/10.1182/bloodadvances.2020004169. IF: 7.5 Q1 B1 IF: 7.5 Q1 B1 IF: 7.5 Q1 B1 IF: 7.5 Q1 B1 IF: 7.5 Q1 B1 IF: 7.5 Q1 B1 IF: 7.5 Q1 B1. Epub 2021/08/31. Sukumar S, Brodsky M, Hussain S, Yanek L, Moliterno A, Brodsky R, et al. Cardiovascular Disease is a leading cause of mortality among ttp survivors in clinical remission. Blood Adv. 2022;6(4):1264–70. https://​doi.​org/​10.​1182/​bloodadvances.​2020004169. IF: 7.5 Q1 B1 IF: 7.5 Q1 B1 IF: 7.5 Q1 B1 IF: 7.5 Q1 B1 IF: 7.5 Q1 B1 IF: 7.5 Q1 B1 IF: 7.5 Q1 B1. Epub 2021/08/31.
15.
go back to reference Bommer M, Wolfle-Guter M, Bohl S, Kuchenbauer F. The Differential diagnosis and treatment of thrombotic microangiopathies. Dtsch Arztebl Int. 2018;115(19):327–34. https://doi.org/10.3238/arztebl.2018.0327. IF: 7.7 Q1 B2 IF: 7.7 Q1 B2 IF: 7.7 Q1 B2 IF: 7.7 Q1 B2 IF: 7.7 Q1 B2 IF: 7.7 Q1 B2 IF: 7.7 Q1 B2. Epub 2018/06/08. Bommer M, Wolfle-Guter M, Bohl S, Kuchenbauer F. The Differential diagnosis and treatment of thrombotic microangiopathies. Dtsch Arztebl Int. 2018;115(19):327–34. https://​doi.​org/​10.​3238/​arztebl.​2018.​0327. IF: 7.7 Q1 B2 IF: 7.7 Q1 B2 IF: 7.7 Q1 B2 IF: 7.7 Q1 B2 IF: 7.7 Q1 B2 IF: 7.7 Q1 B2 IF: 7.7 Q1 B2. Epub 2018/06/08.
16.
go back to reference Balasubramaniyam N, Yandrapalli S, Kolte D, Pemmasani G, Janakiram M, Frishman WH. Cardiovascular Complications and Their Association with mortality in patients with Thrombotic Thrombocytopenic Purpura. Am J Med. 2021;134(2):e89–e97. https://doi.org/10.1016/j.amjmed.2020.06.020. IF: 5.9 Q1 B3 IF: 5.9 Q1 B3 IF: 5.9 Q1 B3 IF: 5.9 Q1 B3 IF: 5.9 Q1 B3 IF: 5.9 Q1 B3 IF: 5.9 Q1 B3. Epub 2020/07/21. Balasubramaniyam N, Yandrapalli S, Kolte D, Pemmasani G, Janakiram M, Frishman WH. Cardiovascular Complications and Their Association with mortality in patients with Thrombotic Thrombocytopenic Purpura. Am J Med. 2021;134(2):e89–e97. https://​doi.​org/​10.​1016/​j.​amjmed.​2020.​06.​020. IF: 5.9 Q1 B3 IF: 5.9 Q1 B3 IF: 5.9 Q1 B3 IF: 5.9 Q1 B3 IF: 5.9 Q1 B3 IF: 5.9 Q1 B3 IF: 5.9 Q1 B3. Epub 2020/07/21.
17.
go back to reference Prevel R, Roubaud-Baudron C, Gourlain S, Jamme M, Peres K, Benhamou Y, et al. Immune Thrombotic Thrombocytopenic Purpura in older patients: prognosis and long-term survival. Blood. 2019;134(24):2209–17. https://doi.org/10.1182/blood.2019000748. IF: 20.3 Q1 B1 IF: 20.3 Q1 B1 IF: 20.3 Q1 B1 IF: 20.3 Q1 B1 IF: 20.3 Q1 B1 IF: 20.3 Q1 B1 IF: 20.3 Q1 B1. Epub 2019/09/19. Prevel R, Roubaud-Baudron C, Gourlain S, Jamme M, Peres K, Benhamou Y, et al. Immune Thrombotic Thrombocytopenic Purpura in older patients: prognosis and long-term survival. Blood. 2019;134(24):2209–17. https://​doi.​org/​10.​1182/​blood.​2019000748. IF: 20.3 Q1 B1 IF: 20.3 Q1 B1 IF: 20.3 Q1 B1 IF: 20.3 Q1 B1 IF: 20.3 Q1 B1 IF: 20.3 Q1 B1 IF: 20.3 Q1 B1. Epub 2019/09/19.
18.
go back to reference Alwan F, Vendramin C, Vanhoorelbeke K, Langley K, McDonald V, Austin S, et al. Presenting Adamts13 antibody and Antigen levels predict prognosis in Immune-mediated thrombotic Thrombocytopenic Purpura. Blood. 2017;130(4):466–71. https://doi.org/10.1182/blood-2016-12-758656. IF: 20.3 Q1 B1 IF: 20.3 Q1 B1 IF: 20.3 Q1 B1 IF: 20.3 Q1 B1 IF: 20.3 Q1 B1 IF: 20.3 Q1 B1 IF: 20.3 Q1 B1. Epub 2017/06/04. Alwan F, Vendramin C, Vanhoorelbeke K, Langley K, McDonald V, Austin S, et al. Presenting Adamts13 antibody and Antigen levels predict prognosis in Immune-mediated thrombotic Thrombocytopenic Purpura. Blood. 2017;130(4):466–71. https://​doi.​org/​10.​1182/​blood-2016-12-758656. IF: 20.3 Q1 B1 IF: 20.3 Q1 B1 IF: 20.3 Q1 B1 IF: 20.3 Q1 B1 IF: 20.3 Q1 B1 IF: 20.3 Q1 B1 IF: 20.3 Q1 B1. Epub 2017/06/04.
19.
go back to reference Benhamou Y, Boelle PY, Baudin B, Ederhy S, Gras J, Galicier L, et al. Cardiac Troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic Thrombocytopenic Purpura. Experience of the French thrombotic microangiopathies Reference Center. J Thromb Haemost. 2015;13(2):293–302. https://doi.org/10.1111/jth.12790. IF: 10.4 Q1 B2 IF: 10.4 Q1 B2 IF: 10.4 Q1 B2 IF: 10.4 Q1 B2 IF: 10.4 Q1 B2 IF: 10.4 Q1 B2 IF: 10.4 Q1 B2. Epub 2014/11/19. Benhamou Y, Boelle PY, Baudin B, Ederhy S, Gras J, Galicier L, et al. Cardiac Troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic Thrombocytopenic Purpura. Experience of the French thrombotic microangiopathies Reference Center. J Thromb Haemost. 2015;13(2):293–302. https://​doi.​org/​10.​1111/​jth.​12790. IF: 10.4 Q1 B2 IF: 10.4 Q1 B2 IF: 10.4 Q1 B2 IF: 10.4 Q1 B2 IF: 10.4 Q1 B2 IF: 10.4 Q1 B2 IF: 10.4 Q1 B2. Epub 2014/11/19.
20.
go back to reference Staley EM, Cao W, Pham HP, Kim CH, Kocher NK, Zheng L, et al. Clinical factors and biomarkers predict outcome in patients with Immune-mediated thrombotic Thrombocytopenic Purpura. Haematologica. 2019;104(1):166–75. https://doi.org/10.3324/haematol.2018.198275. IF: 10.1 Q1 B1 IF: 10.1 Q1 B1 IF: 10.1 Q1 B1 IF: 10.1 Q1 B1 IF: 10.1 Q1 B1 IF: 10.1 Q1 B1 IF: 10.1 Q1 B1. Epub 2018/09/02. Staley EM, Cao W, Pham HP, Kim CH, Kocher NK, Zheng L, et al. Clinical factors and biomarkers predict outcome in patients with Immune-mediated thrombotic Thrombocytopenic Purpura. Haematologica. 2019;104(1):166–75. https://​doi.​org/​10.​3324/​haematol.​2018.​198275. IF: 10.1 Q1 B1 IF: 10.1 Q1 B1 IF: 10.1 Q1 B1 IF: 10.1 Q1 B1 IF: 10.1 Q1 B1 IF: 10.1 Q1 B1 IF: 10.1 Q1 B1. Epub 2018/09/02.
21.
go back to reference Catargi B, Darier R, Montaudon M, Beauvieux MC, Coffin-Boutreux C, Coste P et al. Response to Comment on Gerbaud Et Al. Glycemic Variability Is a Powerful Independent Predictive Factor of Midterm Major Adverse Cardiac Events in Patients with Diabetes with Acute Coronary Syndrome. Diabetes Care. 2019;42:674–681. Diabetes Care (2019) 42(10):e170-e1. Epub 2019/09/22. https://doi.org/10.2337/dci19-0033. IF: 16.2 Q1 B1 IF: 16.2 Q1 B1 IF: 16.2 Q1 B1 IF: 16.2 Q1 B1 IF: 16.2 Q1 B1 IF: 16.2 Q1 B1 IF: 16.2 Q1 B1. Catargi B, Darier R, Montaudon M, Beauvieux MC, Coffin-Boutreux C, Coste P et al. Response to Comment on Gerbaud Et Al. Glycemic Variability Is a Powerful Independent Predictive Factor of Midterm Major Adverse Cardiac Events in Patients with Diabetes with Acute Coronary Syndrome. Diabetes Care. 2019;42:674–681. Diabetes Care (2019) 42(10):e170-e1. Epub 2019/09/22. https://​doi.​org/​10.​2337/​dci19-0033. IF: 16.2 Q1 B1 IF: 16.2 Q1 B1 IF: 16.2 Q1 B1 IF: 16.2 Q1 B1 IF: 16.2 Q1 B1 IF: 16.2 Q1 B1 IF: 16.2 Q1 B1.
22.
go back to reference Mi D, Li Z, Gu H, Jiang Y, Zhao X, Wang Y, et al. Stress hyperglycemia is Associated with in-hospital mortality in patients with diabetes and Acute Ischemic Stroke. CNS Neurosci Ther. 2022;28(3):372–81. https://doi.org/10.1111/cns.13764. IF: 5.5 Q1 B1 IF: 5.5 Q1 B1 IF: 5.5 Q1 B1 IF: 5.5 Q1 B1 IF: 5.5 Q1 B1 IF: 5.5 Q1 B1 IF: 5.5 Q1 B1. Epub 2022/01/28. Mi D, Li Z, Gu H, Jiang Y, Zhao X, Wang Y, et al. Stress hyperglycemia is Associated with in-hospital mortality in patients with diabetes and Acute Ischemic Stroke. CNS Neurosci Ther. 2022;28(3):372–81. https://​doi.​org/​10.​1111/​cns.​13764. IF: 5.5 Q1 B1 IF: 5.5 Q1 B1 IF: 5.5 Q1 B1 IF: 5.5 Q1 B1 IF: 5.5 Q1 B1 IF: 5.5 Q1 B1 IF: 5.5 Q1 B1. Epub 2022/01/28.
23.
go back to reference Luitse MJ, Biessels GJ, Rutten GE, Kappelle LJ. Diabetes, hyperglycaemia, and Acute Ischaemic Stroke. Lancet Neurol. 2012;11(3):261–71. https://doi.org/10.1016/S1474-4422(12)70005-4. IF: 48.0 Q1 B1 IF: 48.0 Q1 B1 IF: 48.0 Q1 B1 IF: 48.0 Q1 B1 IF: 48.0 Q1 B1 IF: 48.0 Q1 B1 IF: 48.0 Q1 B1. Epub 2012/02/22. Luitse MJ, Biessels GJ, Rutten GE, Kappelle LJ. Diabetes, hyperglycaemia, and Acute Ischaemic Stroke. Lancet Neurol. 2012;11(3):261–71. https://​doi.​org/​10.​1016/​S1474-4422(12)70005-4. IF: 48.0 Q1 B1 IF: 48.0 Q1 B1 IF: 48.0 Q1 B1 IF: 48.0 Q1 B1 IF: 48.0 Q1 B1 IF: 48.0 Q1 B1 IF: 48.0 Q1 B1. Epub 2012/02/22.
24.
go back to reference Cui CY, Zhou MG, Cheng LC, Ye T, Zhang YM, Zhu F, et al. Admission hyperglycemia as an independent predictor of long-term prognosis in Acute myocardial infarction patients without diabetes: a retrospective study. J Diabetes Investig. 2021;12(7):1244–51. https://doi.org/10.1111/jdi.13468. IF: 3.2 Q3 B3 IF: 3.2 Q3 B3 IF: 3.2 Q3 B3 IF: 3.2 Q3 B3 IF: 3.2 Q3 B3 IF: 3.2 Q3 B3 IF: 3.2 Q3 B3. Epub 2020/11/30. Cui CY, Zhou MG, Cheng LC, Ye T, Zhang YM, Zhu F, et al. Admission hyperglycemia as an independent predictor of long-term prognosis in Acute myocardial infarction patients without diabetes: a retrospective study. J Diabetes Investig. 2021;12(7):1244–51. https://​doi.​org/​10.​1111/​jdi.​13468. IF: 3.2 Q3 B3 IF: 3.2 Q3 B3 IF: 3.2 Q3 B3 IF: 3.2 Q3 B3 IF: 3.2 Q3 B3 IF: 3.2 Q3 B3 IF: 3.2 Q3 B3. Epub 2020/11/30.
25.
go back to reference Dabke K, Hendrick G, Devkota S. The gut microbiome and metabolic syndrome. J Clin Invest. 2019;129(10):4050–7. https://doi.org/10.1172/JCI129194. IF: 15.9 Q1 B1 IF: 15.9 Q1 B1 IF: 15.9 Q1 B1 IF: 15.9 Q1 B1 IF: 15.9 Q1 B1 IF: 15.9 Q1 B1 IF: 15.9 Q1 B1. Epub 2019/10/02. Dabke K, Hendrick G, Devkota S. The gut microbiome and metabolic syndrome. J Clin Invest. 2019;129(10):4050–7. https://​doi.​org/​10.​1172/​JCI129194. IF: 15.9 Q1 B1 IF: 15.9 Q1 B1 IF: 15.9 Q1 B1 IF: 15.9 Q1 B1 IF: 15.9 Q1 B1 IF: 15.9 Q1 B1 IF: 15.9 Q1 B1. Epub 2019/10/02.
27.
go back to reference Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–5. https://doi.org/10.1161/CIRCULATIONAHA.109.192644. IF: 37.8 Q1 B1 IF: 37.8 Q1 B1 IF: 37.8 Q1 B1 IF: 37.8 Q1 B1 IF: 37.8 Q1 B1 IF: 37.8 Q1 B1 IF: 37.8 Q1 B1. Epub 2009/10/07. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–5. https://​doi.​org/​10.​1161/​CIRCULATIONAHA.​109.​192644. IF: 37.8 Q1 B1 IF: 37.8 Q1 B1 IF: 37.8 Q1 B1 IF: 37.8 Q1 B1 IF: 37.8 Q1 B1 IF: 37.8 Q1 B1 IF: 37.8 Q1 B1. Epub 2009/10/07.
28.
go back to reference Ingels C, Vanhorebeek I, Van den Berghe G. Glucose homeostasis, Nutrition and infections during critical illness. Clin Microbiol Infect. 2018;24(1):10–5. https://doi.org/10.1016/j.cmi.2016.12.033. IF: 14.2 Q1 B1 IF: 14.2 Q1 B1 IF: 14.2 Q1 B1 IF: 14.2 Q1 B1 IF: 14.2 Q1 B1 IF: 14.2 Q1 B1 IF: 14.2 Q1 B1. Epub 2017/01/14. Ingels C, Vanhorebeek I, Van den Berghe G. Glucose homeostasis, Nutrition and infections during critical illness. Clin Microbiol Infect. 2018;24(1):10–5. https://​doi.​org/​10.​1016/​j.​cmi.​2016.​12.​033. IF: 14.2 Q1 B1 IF: 14.2 Q1 B1 IF: 14.2 Q1 B1 IF: 14.2 Q1 B1 IF: 14.2 Q1 B1 IF: 14.2 Q1 B1 IF: 14.2 Q1 B1. Epub 2017/01/14.
29.
go back to reference Paolisso P, Foa A, Bergamaschi L, Angeli F, Fabrizio M, Donati F, et al. Impact of admission hyperglycemia on short and long-term prognosis in Acute myocardial infarction: Minoca Versus Mioca. Cardiovasc Diabetol. 2021;20(1):192. https://doi.org/10.1186/s12933-021-01384-6. IF: 9.3 Q1 B1 IF: 9.3 Q1 B1 IF: 9.3 Q1 B1 IF: 9.3 Q1 B1 IF: 9.3 Q1 B1 IF: 9.3 Q1 B1 IF: 9.3 Q1 B1. Epub 2021/09/26. Paolisso P, Foa A, Bergamaschi L, Angeli F, Fabrizio M, Donati F, et al. Impact of admission hyperglycemia on short and long-term prognosis in Acute myocardial infarction: Minoca Versus Mioca. Cardiovasc Diabetol. 2021;20(1):192. https://​doi.​org/​10.​1186/​s12933-021-01384-6. IF: 9.3 Q1 B1 IF: 9.3 Q1 B1 IF: 9.3 Q1 B1 IF: 9.3 Q1 B1 IF: 9.3 Q1 B1 IF: 9.3 Q1 B1 IF: 9.3 Q1 B1. Epub 2021/09/26.
30.
go back to reference Mjos OD. Effect of free fatty acids on myocardial function and oxygen consumption in Intact Dogs. J Clin Invest. 1971;50(7):1386–9. https://doi.org/10.1172/JCI106621. IF: 15.9 Q1 B1 IF: 15.9 Q1 B1 IF: 15.9 Q1 B1 IF: 15.9 Q1 B1 IF: 15.9 Q1 B1 IF: 15.9 Q1 B1 IF: 15.9 Q1 B1. Epub 1971/07/01. Mjos OD. Effect of free fatty acids on myocardial function and oxygen consumption in Intact Dogs. J Clin Invest. 1971;50(7):1386–9. https://​doi.​org/​10.​1172/​JCI106621. IF: 15.9 Q1 B1 IF: 15.9 Q1 B1 IF: 15.9 Q1 B1 IF: 15.9 Q1 B1 IF: 15.9 Q1 B1 IF: 15.9 Q1 B1 IF: 15.9 Q1 B1. Epub 1971/07/01.
Metadata
Title
Stress-induced hyperglycemia is associated with the mortality of thrombotic thrombocytopenic purpura patients
Authors
Lingling Hu
Jing Wang
Xiaxia Jin
Guoguang Lu
Meidan Fang
Jian Shen
Tao-Hsin Tung
Bo Shen
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2024
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/s13098-024-01275-2

Other articles of this Issue 1/2024

Diabetology & Metabolic Syndrome 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.